Operating Income (Loss) of Rubius Therapeutics, Inc. from 31 Dec 2016 to 31 Dec 2022
- Taxonomy & unit
- us-gaap: USD
- Description
- The net result for the period of deducting operating expenses from operating revenues.
- Summary
-
Rubius Therapeutics, Inc. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2016 to 31 Dec 2022.
- Rubius Therapeutics, Inc. Operating Income (Loss) for the quarter ending 31 Dec 2022 was $23,096,000, a 57% increase year-over-year.
- Rubius Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 31 Dec 2022 was $178,446,000, a 8.3% increase year-over-year.
- Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $178,446,000, a 8.3% increase from 2021.
- Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2021 was $194,616,000, a 17% decline from 2020.
- Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2020 was $166,448,000, a 1.9% increase from 2019.
- Source SEC data
- View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)
Rubius Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2022 | $178,446,000 | $23,096,000 | +$30,631,000 | +57% | 01 Oct 2022 | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2022 | $209,077,000 | $61,582,000 | -$11,533,000 | -23% | 01 Jul 2022 | 30 Sep 2022 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2022 | $197,544,000 | $42,906,000 | +$7,017,000 | +14% | 01 Apr 2022 | 30 Jun 2022 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2022 | $204,561,000 | $50,862,000 | -$9,945,000 | -24% | 01 Jan 2022 | 31 Mar 2022 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2021 | $194,616,000 | $53,727,000 | -$14,011,000 | -35% | 01 Oct 2021 | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| Q3 2021 | $180,605,000 | $50,049,000 | -$9,864,000 | -25% | 01 Jul 2021 | 30 Sep 2021 | 10-Q | 09 Nov 2022 | 2022 | Q3 |
| Q2 2021 | $170,741,000 | $49,923,000 | -$12,226,000 | -32% | 01 Apr 2021 | 30 Jun 2021 | 10-Q | 09 Aug 2022 | 2022 | Q2 |
| Q1 2021 | $158,515,000 | $40,917,000 | +$7,933,000 | +16% | 01 Jan 2021 | 31 Mar 2021 | 10-Q | 10 May 2022 | 2022 | Q1 |
| Q4 2020 | $166,448,000 | $39,716,000 | +$5,712,000 | +13% | 01 Oct 2020 | 31 Dec 2020 | 10-K | 23 Feb 2021 | 2020 | FY |
| Q3 2020 | $172,160,000 | $40,185,000 | +$8,297,000 | +17% | 01 Jul 2020 | 30 Sep 2020 | 10-Q | 08 Nov 2021 | 2021 | Q3 |
| Q2 2020 | $180,457,000 | $37,697,000 | +$3,588,000 | +8.7% | 01 Apr 2020 | 30 Jun 2020 | 10-Q | 09 Aug 2021 | 2021 | Q2 |
| Q1 2020 | $184,045,000 | $48,850,000 | -$14,444,000 | -42% | 01 Jan 2020 | 31 Mar 2020 | 10-Q/A | 20 Aug 2021 | 2021 | Q1 |
| Q4 2019 | $169,601,000 | $45,428,000 | -$16,306,000 | -56% | 01 Oct 2019 | 31 Dec 2019 | 10-K | 23 Feb 2021 | 2020 | FY |
| Q3 2019 | $153,295,000 | $48,482,000 | -$20,928,000 | -76% | 01 Jul 2019 | 30 Sep 2019 | 10-K | 23 Feb 2021 | 2020 | FY |
| Q2 2019 | $132,367,000 | $41,285,000 | -$20,901,000 | -103% | 01 Apr 2019 | 30 Jun 2019 | 10-K | 23 Feb 2021 | 2020 | FY |
| Q1 2019 | $111,466,000 | $34,406,000 | -$19,803,000 | -136% | 01 Jan 2019 | 31 Mar 2019 | 10-K | 23 Feb 2021 | 2020 | FY |
| Q4 2018 | $91,663,000 | $29,122,000 | -$11,649,000 | -67% | 01 Oct 2018 | 31 Dec 2018 | 10-K | 12 Mar 2020 | 2019 | FY |
| Q3 2018 | $80,014,000 | $27,554,000 | -$15,579,000 | -130% | 01 Jul 2018 | 30 Sep 2018 | 10-K | 12 Mar 2020 | 2019 | FY |
| Q2 2018 | $64,435,000 | $20,384,000 | -$11,351,000 | -126% | 01 Apr 2018 | 30 Jun 2018 | 10-K | 12 Mar 2020 | 2019 | FY |
| Q1 2018 | $53,084,000 | $14,603,000 | -$9,820,000 | -205% | 01 Jan 2018 | 31 Mar 2018 | 10-K | 12 Mar 2020 | 2019 | FY |
| Q4 2017 | $43,264,000 | $17,473,000 | 01 Oct 2017 | 31 Dec 2017 | 10-K | 28 Mar 2019 | 2018 | FY | ||
| Q3 2017 | $11,975,000 | 01 Jul 2017 | 30 Sep 2017 | 10-K | 28 Mar 2019 | 2018 | FY | |||
| Q2 2017 | $9,033,000 | 01 Apr 2017 | 30 Jun 2017 | 10-K | 28 Mar 2019 | 2018 | FY | |||
| Q1 2017 | $4,783,000 | 01 Jan 2017 | 31 Mar 2017 | 10-K | 28 Mar 2019 | 2018 | FY |
Rubius Therapeutics, Inc. Annual Operating Income (Loss) (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2022 | $178,446,000 | +$16,170,000 | +8.3% | 01 Jan 2022 | 31 Dec 2022 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2021 | $194,616,000 | -$28,168,000 | -17% | 01 Jan 2021 | 31 Dec 2021 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2020 | $166,448,000 | +$3,153,000 | +1.9% | 01 Jan 2020 | 31 Dec 2020 | 10-K | 27 Feb 2023 | 2022 | FY |
| 2019 | $169,601,000 | -$77,938,000 | -85% | 01 Jan 2019 | 31 Dec 2019 | 10-K | 25 Feb 2022 | 2021 | FY |
| 2018 | $91,663,000 | -$48,399,000 | -112% | 01 Jan 2018 | 31 Dec 2018 | 10-K | 23 Feb 2021 | 2020 | FY |
| 2017 | $43,264,000 | -$32,412,000 | -299% | 01 Jan 2017 | 31 Dec 2017 | 10-K | 12 Mar 2020 | 2019 | FY |
| 2016 | $10,852,000 | 01 Jan 2016 | 31 Dec 2016 | 10-K | 28 Mar 2019 | 2018 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.